Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Determine the Maximum Tolerated Dose of Liposome-Encapsulated C-RAF Antisense Oligodeoxynucleotide (LErafAON) in Patients With Advanced Solid Tumors

NCT00024661 is registered in ClinicalTrials.gov with INSYS Therapeutics Inc as lead sponsor.

NCT NCT00024661
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00024661 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Determine the Maximum Tolerated Dose of Liposome-Encapsulated C-RAF Antisense Oligodeoxynucleotide (LErafAON) in Patients With Advanced Solid Tumors
Lead sponsor
INSYS Therapeutics Inc
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2001
Completion date
October 31, 2004
Enrollment
30
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms